Literature DB >> 25422341

Anal tuberculosis complicating anti-TNFα therapy.

Nuria Luquín1, Mar Masiá2, Raúl Noguera3, Félix Gutiérrez4.   

Abstract

A 42-year-old man receiving anti-tumour necrosis factor α (anti-TNFα) therapy with adalimumab due to psoriatic arthritis presented with a 2-month-old anal ulcer. An apical right lung infiltrate was found in his chest X-ray, although he had no pulmonary symptoms. Two biopsies of the ulcer were taken and reported as granulomatous, necrotising, with chronic inflammation (first), and as hyperplasic epidermis with linfocitary infiltrate and the presence of plenty of plasmatic cells (second). Histochemical techniques, including Ziehl-Neelsen, Grocott and periodic acid-Schiff stains, and PCR for Mycobacterium tuberculosis on both biopsies were negative. Serology for HIV, syphilis and hepatitis were also negative. In the second biopsy culture, moderate colonies of M. tuberculosis finally grew. The patient started a four-drug antituberculosis regimen. Adalimumab was discontinued and etanercept introduced after 2 months of antituberculosis therapy. The patient remained on therapy for 9 months with complete ulcer resolution. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25422341      PMCID: PMC4244408          DOI: 10.1136/bcr-2014-206976

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.

Authors:  Chrisoula Hatzara; Emilia Hadziyannis; Anna Kandili; Christos Koutsianas; Anastasia Makris; Georgios Georgiopoulos; Dimitrios Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2014-05-22       Impact factor: 19.103

2.  Resistance to first-line antituberculosis drugs in Spain, 2010-2011. RETUBES Study.

Authors:  Rafael Blanquer; Teresa Rodrigo; Martí Casals; Juan Ruiz Manzano; José María García-García; José Luís Calpe; Eulalia Valencia; Teresa Pascual; Isabel Mir; María Ángeles Jiménez; Fernando Cañas; Rafael Vidal; Antón Penas; Joan A Caylà
Journal:  Arch Bronconeumol       Date:  2014-07-11       Impact factor: 4.872

3.  Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.

Authors:  Elizabeth C Hsia; John J Cush; Eric L Matteson; Anna Beutler; Mittie K Doyle; Benjamin Hsu; Stephen Xu; Mahboob U Rahman
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-02       Impact factor: 4.794

4.  Mycobacterial diseases and antitumour necrosis factor therapy in USA.

Authors:  K L Winthrop; R Baxter; L Liu; C D Varley; J R Curtis; J W Baddley; B McFarland; D Austin; L Radcliffe; Eb Suhler; D Choi; J T Rosenbaum; L J Herrinton
Journal:  Ann Rheum Dis       Date:  2012-04-20       Impact factor: 19.103

5.  Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.

Authors:  Der-Yuan Chen; Gwan-Han Shen; Yi-Ming Chen; Hsin-Hua Chen; Chia-Wei Hsieh; Joung-Liang Lan
Journal:  Ann Rheum Dis       Date:  2011-10-21       Impact factor: 19.103

Review 6.  Ano-perianal tuberculosis--solving a clinical dilemma.

Authors:  P J Gupta
Journal:  Afr Health Sci       Date:  2005-12       Impact factor: 0.927

7.  Ano-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan.

Authors:  W-C Tai; T-H Hu; C-H Lee; H-H Chen; C-C Huang; S-K Chuah
Journal:  Colorectal Dis       Date:  2009-10-13       Impact factor: 3.788

Review 8.  Anal tuberculosis: report of a case and review of literature.

Authors:  Soniya Mathew
Journal:  Int J Surg       Date:  2006-12-02       Impact factor: 6.071

Review 9.  Tuberculosis of the gastrointestinal tract and peritoneum.

Authors:  J B Marshall
Journal:  Am J Gastroenterol       Date:  1993-07       Impact factor: 10.864

10.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; J Galloway; A Ustianowski; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2009-10-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.